Jean-Charles Soria to Programmed Cell Death 1 Receptor
This is a "connection" page, showing publications Jean-Charles Soria has written about Programmed Cell Death 1 Receptor.
Connection Strength
1.812
-
JAK Mutations as Escape Mechanisms to Anti-PD-1 Therapy. Cancer Discov. 2017 02; 7(2):128-130.
Score: 0.462
-
Bull Cancer. 2018 Dec; 105 Suppl 1:S59-S67.
Score: 0.131
-
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. JAMA Oncol. 2018 11 01; 4(11):1543-1552.
Score: 0.130
-
Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. Clin Cancer Res. 2019 02 01; 25(3):946-956.
Score: 0.130
-
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018 09; 19(9):1180-1191.
Score: 0.128
-
Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression. Eur J Cancer. 2018 09; 101:160-164.
Score: 0.128
-
Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer. 2018 03; 91:21-29.
Score: 0.123
-
Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer. 2018 01; 88:38-47.
Score: 0.122
-
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? Eur J Cancer. 2017 12; 87:65-74.
Score: 0.122
-
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018 Jan 05; 359(6371):91-97.
Score: 0.122
-
Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors). Eur J Cancer. 2017 10; 84:202-211.
Score: 0.120
-
Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol. 2018 12; 15(12):748-762.
Score: 0.033
-
[Hodgkin lymphoma: Current and future therapeutic strategies]. Bull Cancer. 2018 Jan; 105(1):81-98.
Score: 0.031
-
Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. Eur J Cancer. 2017 09; 82:34-44.
Score: 0.030